Liquid Biopsy as a New Tool for Diagnosis and Monitoring in Renal Cell Carcinoma DOI Open Access
Giuseppe Stefano Netti, Federica De Luca,

Valentina Camporeale

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1442 - 1442

Published: April 25, 2025

Renal cell carcinoma (RCC) presents a significant diagnostic challenge, particularly in small renal masses. The search for non-invasive screening methods and biomarkers has directed research toward liquid biopsy, which focuses on microRNAs (miRNAs), exosomes, circulating tumor cells (CTCs). miRNAs are non-coding RNA molecules that show considerable dysregulation RCC, they have potential both prognostic applications. Research highlighted their utility biofluids, such as plasma, serum, urine, detecting RCC characterizing its subtypes. Promising miRNA signatures been associated with overall survival, suggesting importance the management of RCC. Exosomes, carry variety molecular components, including miRNAs, emerging valuable biomarkers, whereas CTCs, released from primary tumors into bloodstream, provide critical information cancer progression. However, translation these findings clinical practice requires additional validation standardization through large-scale studies robust evidence. Although there currently no approved tests future biopsy monitoring, treatment decision-making, outcome prediction patients this disease is significant. This review examined discussed recent developments assessing strengths limitations approaches managing disease.

Language: Английский

The microRNA landscape and regulatory network in Clonorchis sinensis-infected hepatocellular carcinoma: implications for tumor progression DOI Creative Commons
Caibiao Wei,

Junxian Chen,

Tim Huang

et al.

Parasites & Vectors, Journal Year: 2025, Volume and Issue: 18(1)

Published: Feb. 21, 2025

Language: Английский

Citations

0
Liquid Biopsy as a New Tool for Diagnosis and Monitoring in Renal Cell Carcinoma DOI Open Access
Giuseppe Stefano Netti, Federica De Luca,

Valentina Camporeale

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1442 - 1442

Published: April 25, 2025

Renal cell carcinoma (RCC) presents a significant diagnostic challenge, particularly in small renal masses. The search for non-invasive screening methods and biomarkers has directed research toward liquid biopsy, which focuses on microRNAs (miRNAs), exosomes, circulating tumor cells (CTCs). miRNAs are non-coding RNA molecules that show considerable dysregulation RCC, they have potential both prognostic applications. Research highlighted their utility biofluids, such as plasma, serum, urine, detecting RCC characterizing its subtypes. Promising miRNA signatures been associated with overall survival, suggesting importance the management of RCC. Exosomes, carry variety molecular components, including miRNAs, emerging valuable biomarkers, whereas CTCs, released from primary tumors into bloodstream, provide critical information cancer progression. However, translation these findings clinical practice requires additional validation standardization through large-scale studies robust evidence. Although there currently no approved tests future biopsy monitoring, treatment decision-making, outcome prediction patients this disease is significant. This review examined discussed recent developments assessing strengths limitations approaches managing disease.

Language: Английский

Citations

0